Combination Treatment with Sorafenib and Wh-4 Additively Suppresses the Proliferation of Liver Cancer Cells

Su-Hong Chen,Dan-Dan Xu,Peng-Jun Zhou,Yao Wang,Qiu-Ying Liu,Zhe Ren,Zhong Liu,Xia Wang,Hui-Qing Huang,Xue,Ying Wang,Yi-Fei Wang
DOI: https://doi.org/10.3892/etm.2022.11156
IF: 2.7
2022-01-01
Experimental and Therapeutic Medicine
Abstract:Sorafenib is currently used to treat hepatocellular carcinoma (HCC). However, the development of chemoresistance to sorafenib is a major limitation for sorafenib-based therapy in patients with HCC. In the present study, the effect of the combination therapy of sorafenib and wh-4 on the proliferation of liver cancer cells was investigated. The results showed that sorafenib with wh-4 additively suppressed the proliferation of liver cancer cells. The colony formation of liver cancer cells decreased significantly in response to the combination treatment of sorafenib with wh-4, and it also induced the apoptosis of liver cancer cells. Western blot analysis demonstrated decreased expression of Bcl2, and increased expression of Bax in liver cancer cells treated with a combination of sorafenib and wh-4. Moreover, the migration of liver cancer cells was inhibited. The combination treatment of sorafenib with wh-4 reduced the expression levels of ABCB1 and ABCG2 which are responsible for resistance. Finally, STAT3 overexpression abolished the proliferation inhibition effect of sorafenib with wh-4 on liver cancer cells, and sorafenib and wh-4 suppressed the proliferation of liver cancer cells by STAT3 pathway. Together, these results suggest that sorafenib-wh4 combination treatment is a potential novel therapeutic approach to suppress the proliferation of liver cancer cells.
What problem does this paper attempt to address?